Table 2.

Patients, disease, and transplant characteristics.

Total cohort	96 patients
Sex M/F	57 (70%)/39 (30%)
Age at transplant	56 years (17–73)
Cytogenetic risk (28)  Favorable  Intermediate  Adverse	4 (4%) 79 (82%) 13 (14%)
ELN risk (7)  Favorable  Intermediate  Adverse	15 (16%) 43 (45%) 38 (39%)
Line of treatment before HSCT n.  None  1  2  3	4 (4%) 69 (72%) 19 (20%) 4 (4%)
Median time to transplant	183.5 days (30 to 645)
HCT-CI  0  1  2  3  4  ≥5	9 (9%) 11 (11%) 17 (18%) 18 (19%) 23 (24%) 18 (19%)
Year of transplant  2016–2018  2019–2021	29 (30%) 67 (70%)
Disease status at transplant  Never treated  CR1  CR2  PR  Relapse/refractory	6 (6%) 54 (56%) 12 (13%) 6 (6%) 18 (19%)
Conditioning  ABL  RIC/NMA	42 (44%) 54 (56%)
Donor  HLA Id Sibling  Haploidentical  Mismatched unrelated  Matched unrelated	21 (22%) 32 (33%) 15 (16%) 28 (29%)
Stem cell source  PB  CB  BM	67 (70%) 4 (4%) 25 (26%)
GvHD prophylaxis  CSA+Cy  CSA+MFA+Cy  CSA+MFA  CSA+MTX	4 (4%) 70 (73%) 2 (2%) 20 (21%)
ATG	18 (19%)

M, male; F, female; HCT-CI, hematopoietic cell transplant comorbidity index; CR, complete remission; PR, partial response; ABL, myeloablative; RIC, reduced intensity conditioning; NMA, non-myeloablative conditioning; PB, peripheral blood; CB, cord blood; BM, bone marrow; CSA, cyclosporine A; MFA, micofenolic acid; MTX, methotrexate; CY, cyclophosphamide post-transplant; ATG, anti-thymocyte globulins.